Evaluation of Xpert ^® MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda.

ABSTRACT:

Background

Drug-Resistant Tuberculosis (DR-TB) is one of the key challenges toward TB control. There is an urgent need for rapid and accurate drug susceptibility tests (DST) for the most commonly used 1 ^st and 2 ^nd line TB drugs.

Design and methods

In a blinded, laboratory-based cross-sectional study, we set out to validate the performance of the Xpert ^® MTB/XDR test for DST of M. tuberculosis . Sputum samples or culture isolates collected between January 2020 and December 2021 from patients with rifampicin resistance -TB and/or with higher suspicion index for isoniazid (INH) resistance and/or 2 ^nd line fluoroquinolones (FQ) and injectable agents (IAs) were tested using the Xpert ^® MTB/XDR test from 11/September 2

SUBMITTER: Katamba A 

PROVIDER: S-EPMC10104194 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature